| Original language | English |
|---|---|
| Article number | mdz184 |
| Pages (from-to) | 1028-1031 |
| Number of pages | 4 |
| Journal | Annals of Oncology |
| Volume | 30 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 1 Jul 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Oncology, Vol. 30, No. 7, mdz184, 01.07.2019, p. 1028-1031.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - Hyperprogression during immunotherapy
T2 - do we really want to know?
AU - Champiat, S.
AU - Besse, B.
AU - Marabelle, A.
N1 - Funding Information: SC has received honoraria from Amgen, AstraZeneca, BMS, Janssen, MSD, Novartis, and Roche. AM has received honoraria or consulting fees from the following companies: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Roche/Genentech, Merck (MSD), Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, SOTIO, Pillar Partners, BPI. As part of the Drug Development Department (DITEP) SC and AM are Principal/sub-Investigator of Clinical Trials for Abbvie, Aduro biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Aeneca, Astra Zeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Inc, Bristol Myers Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai Pharmaceutical Co, Clovis Oncology, Daiichi Sankyo, Debiopharm S.a, Eisai, Eli lilly, Exelixis, Forma, Gamamabs, Genentech, Inc, Gilead Sciences, Inc, Glaxosmithkline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev., Inc, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Kgaa, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre Medicament, Plexxikon, Rigontec Gmbh, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth Pharmaceuticals France, Xencor, Y's Therapeutics. As part of the Drug Development Department (DITEP), SC and AM received research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi, non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. BB has received sponsored research at Gustave Roussy Cancer Center from Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma.
PY - 2019/7/1
Y1 - 2019/7/1
UR - http://www.scopus.com/inward/record.url?scp=85071105791&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdz184
DO - 10.1093/annonc/mdz184
M3 - Editorial
C2 - 31173063
AN - SCOPUS:85071105791
SN - 0923-7534
VL - 30
SP - 1028
EP - 1031
JO - Annals of Oncology
JF - Annals of Oncology
IS - 7
M1 - mdz184
ER -